The effective doses of remimazolam besylate in the procedural sedation of endoscopic retrograde cholangiopancreatography [PDF]
This study aimed to determine the values of the half‐effective dose (ED50) and 95% effective dose (ED95) of remimazolam besylate used in the procedural sedation of endoscopic retrograde cholangiopancreatography (ERCP).
Yu Wanqiu, Dan-Dan Tan, Juan Li
exaly +7 more sources
Determination of ED50 and ED95 of remimazolam besylate combined with alfentanil for adult gastroscopy: a prospective dose-finding study [PDF]
Background: To explore the median effective dose (ED50) and 95% effective dose (ED95) of remimazolam besylate combined with alfentanil for adult gastroscopy.
Pingjuan Wang +2 more
exaly +8 more sources
The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy [PDF]
ObjectiveRemimazolam besylate and Ciprofol are newer sedatives used in minor surgeries. Propofol is a classic drug mainly used for short surgeries.
Haiyan Lan, Qiaomin Xu
exaly +8 more sources
Evaluation of deep sedation effects and respiratory aspects of remimazolam besylate in elderly patients undergoing fiberoptic bronchoscopy [PDF]
BackgroundThe geriatric population, especially individuals over 65 years old with comorbidities classified by the ASA (American Society of Anesthesiologists) grading system, requires careful sedation management during flexible bronchoscopy (FB) to reduce
Dongmei Ma +4 more
exaly +8 more sources
Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase Ⅲ trial [PDF]
Study objective: The objective of the study was to evaluate the safety and efficacy of remimazolam besylate versus propofol injection in patients undergoing colonoscopy.Design: A multicenter, randomized, non-inferiority, single-blind, parallel-controlled
Ximei Wang +7 more
exaly +6 more sources
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial [PDF]
Background Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues.
Xiaoqiang Zhang, Shuang Li, Jing Liu
exaly +6 more sources
Comparative Evaluation of Remimazolam Besylate versus Propofol for Pediatric MRI Sedation: Safety, Recovery, and Adverse Event Profiles [PDF]
Haibi Shi, Jinxian Zhu, Jieru Liu, Jun Cai, Ling Wang, Jian’e Yan Department of Anesthesiology, Lianyungang Maternal and Child Health Hospital, Lianyungang, Jiangsu, 222000, People’s Republic of ChinaCorrespondence: Jian’e Yan, Department of ...
Shi H +5 more
exaly +7 more sources
Efficacy and safety of remimazolam besylate in bronchoscopy for adults: A multicenter, randomized, double-blind, positive-controlled clinical study [PDF]
Background: With the development of fiberoptic bronchoscopy in the diagnosis and treatment of various pulmonary diseases, the anesthesia/sedation requirements are becoming more demanding, posing great challenges for patient safety while ensuring a smooth
Xiao-Min Wu
exaly +6 more sources
Long-term sedation with remimazolam besylate versus propofol in critically ill patients during invasive mechanical ventilation: a study protocol for a multicenter randomized non-inferior trial [PDF]
Background: Remimazolam besylate is a novel ultra-short-acting benzodiazepine that can potentially be a safe and effective sedative in intensive care units. This study aims to assess whether remimazolam besylate is not inferior to propofol in maintaining
Xiaobo Yang +2 more
exaly +4 more sources
Effect of propofol combined with remimazolam besylate on blood pressure during general anesthesia induction in patients undergoing gynecological laparoscopic surgery: single-centre randomized controlled trial [PDF]
Background Hypotension often occurs during intraoperative anesthesia induction in gynecological laparoscopic surgery. Remimazolam is reportedly associated with lesser intraoperative hypotension than propofol.
Xinmin Zhao +4 more
exaly +3 more sources

